NEW YORK
--(BUSINESS WIRE)--Jul. 25, 2018--
Piper Jaffray Companies
(NYSE: PJC), a leading investment bank and asset management firm, is pleased to announce the hiring of
Danielle Brill
and
Joe Catanzaro
as senior research analysts in its healthcare equity research group. Covering the biotech sector, Brill and Catanzaro will be based in the firm’s
New York
office.
“Biopharma is core to our strategy at
Piper Jaffray
and these hires demonstrate our commitment to providing our institutional and corporate clients with the highest-quality equity research in the industry,” said
Michael Cox
, co-head of global equities at
Piper Jaffray
. “When combined with recent additions in sales and trading, we now have one of the broadest biopharma equities platforms on
Wall Street
.”
Brill has more than 10 years’ experience in the pharmaceutical industry. Prior to joining
Piper Jaffray
, Brill was an analyst with
Needham & Company
covering smid-cap biotech companies. Brill also worked as a clinical pharmacist at
Mount Sinai Hospital
and
Premier Inc.
, and as a senior research technician at
New York University
and
Columbia University Medical Center
. She received a bachelor’s degree in biology from
Michigan State University
and earned a doctorate of pharmacy from Ernest Mario
School of Pharmacy at Rutgers University
.
Prior to joining
Piper Jaffray
, Catanzaro was a biotech equity research associate at
Cowen Inc.
, where he led the production of Cowen’s biannual
Investor’s Guide to Immuno-Oncology
. Prior to
Cowen Inc.
, Catanzaro served as a graduate research assistant at
Stony Brook University School of Medicine
and authored several publications in peer-reviewed journals. Catanzaro received a bachelor’s degree in biology from
Binghamton University
and earned a doctorate in genetics from
Stony Brook University School of Medicine
.
Piper Jaffray Companies
(NYSE: PJC) is a leading investment bank and asset management firm. Securities brokerage and investment banking services are offered in the U.S. through
Piper Jaffray & Co.
, member
SIPC
and FINRA; in
Europe
through
Piper Jaffray Ltd.
, authorized and regulated by the
U.K. Financial Conduct Authority
; and in
Hong Kong
through
Piper Jaffray Hong Kong Limited
, authorized and regulated by the
Securities and Futures Commission
. Asset management products and services are offered through five separate investment advisory affiliates―U.S. Securities and Exchange Commission (
SEC
) registered
Advisory Research, Inc.
,
Piper Jaffray Investment Management LLC
,
PJC Capital Partners LLC
and
Piper Jaffray & Co.
, and Guernsey-based
Parallel General Partners Limited
, authorized and regulated by the
Guernsey Financial Services Commission
.
Follow
Piper Jaffray
:
LinkedIn
|
Facebook
|
Twitter
© 2018
Piper Jaffray Companies
. 800 Nicollet Mall, Suite 1000,
Minneapolis, Minnesota
55402-7036
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180725005503/en/
Source:
Piper Jaffray Companies
Piper Jaffray Companies
Pamela Steensland, 612-303-8185
pamela.k.steensland@pjc.com
